KOD News and Press, Kodiak Sciences Inc From 04/21/25

2025-04-21 11:57:19 ET Kodiak Sciences Inc. (NASDAQ: KOD) is one of today’s top gainers. The company’s shares have moved 12.5% on the day to $3.19. Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics t...

2025-03-27 17:00:30 ET More on Kodiak Sciences Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders Seeking Alpha’s Quant Rating on Kodiak Sciences Historical earnings data for Kodiak Sciences Financial information for Kodiak Sciences ...

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results PR Newswire PALO ALTO, Calif. , March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial...

HG Holdings Inc (STLY) is expected to report for quarter end 2024-12-31 Savara Inc. (SVRA) is expected to report $-0.11 for Q4 2024 Reborn Coffee Inc. (REBN) is expected to report for quarter end 2024-12-31 VSee Health Inc. (VSEE) is expected to report for Q4 2024 IceCure Medical ...

2025-03-12 23:56:16 ET Summary Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B, with 26 significant positions making up the majority of the portfolio. The top five holdings—Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Insmed—constitute app...

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy PR Newswire Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met p...

2025-02-23 20:08:22 ET Summary Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD’s pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM b...

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025 PR Newswire PALO ALTO, Calif. , Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transform...

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire PALO ALTO, Calif. , Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing trans...